New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 8, 2013, Pages 1029-1038

  Salama, Joseph K ^a   Vokes, Everett E ^b,c  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; TEGAFUR; URACIL; VINDESINE;

CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; CYTOTOXICITY; DISTANT METASTASIS; DRUG EFFICACY; ESOPHAGITIS; FAILURE FREE SURVIVAL; HUMAN; INDUCTION CHEMOTHERAPY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHOTON THERAPY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE ESCALATION; REVIEW; SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROTONS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE;

EID: 84875944153     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.5064     Document Type: Review

References (96)

1. Curran WJ Jr, Paulus R, Langer CJ, et al: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452-1460, 2011
2. Fournel P, Robinet G, Thomas P, et al: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23:5910-5917, 2005
3. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699, 1999 (Pubitemid 29415225)
4. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
5. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin andradiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
6. Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 46:87-98, 2004 (Pubitemid 39201387)
7. Govindan R, Bogart J, Stinchcombe T, et al: Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 29:3120-3125, 2011
8. Hanna N, Neubauer M, Yiannoutsos C, et al: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III nonsmall-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755-5760, 2008
9. Vokes EE, Herndon JE 2nd, Kelley MJ, et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Nonsmall-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-1704, 2007 (Pubitemid 46797950)
10. Vokes EE, Herndon JE 2nd, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191-4198, 2002 (Pubitemid 35191021)
11. Maemondo M, Sugawara S, Ishida T, et al: Randomized phase II trial of tegafur-uracil (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small cell lung cancer: NJLCG 0601. J Clin Oncol 28:535s, 2010 (suppl 15; abstr 7083)
12. Satouchi M, Yamamoto N, Chiba Y, et al: Randomized, phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small cell lung cancer (NSCLC): WJTOG0105. J Clin Oncol 27:383s, 2009 (suppl 18; 7504)
13. Wang L, Wu S, Ou G, et al: Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 77:89-96, 2012
14. Seiwert TY, Connell PP, Mauer AM, et al: A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 13:515-522, 2007 (Pubitemid 46225357)
15. Xu Y, Ma S, Ji Y, et al: Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. Lung Cancer 72:327-332, 2011
16. Ciuleanu TE, Brodowicz T, Belani CP, et al: Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 26:426s, 2008 (suppl 15; abstr 8011)
17. Peterson P, Park K, Fossella F: Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2:S851, 2007 (suppl 4)
18. Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 14:253-263, 2009
19. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
20. Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107: 1589-1596, 2006 (Pubitemid 44546920)
21. Sigmond J, Backus HH, Wouters D, et al: Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66:431-438, 2003 (Pubitemid 36937028)
22. Kim S, Kim M, Choi E: Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small-cell lung cancer (NSCLC): Randomized phase III trial. J Clin Oncol 25:391s, 2007 (suppl 18; abstr 7528)
23. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883-5891, 2005
24. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010, 2003 (Pubitemid 46606390)
25. Yamamoto S, Tsujino K, Ando M, et al: Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced nonsmall cell lung cancer? A pooled analysis of the literature. J Clin Oncol 30:452s, 2012 (suppl 15; abstr 7000)
26. Huber RM, Engel-Riedel W, Kollmeier J, et al: GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study. J Clin Oncol 30:452s, 2012 (suppl 15; abstr 7001)
27. Kim Y, Choi E, Lee J, et al: Consolidation chemotherapy with monthly paclitaxel and cisplatin (PC) or observation after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC): Randomized phase II study. J Thorac Oncol 2:S449-S450, 2007 (abstr PD4-1-7)
28. Colin P, Ganem G, Duhamel J, et al: Impact of paclitaxel-carboplatin (PC) consolidation chemotherapy versus observation after weekly PC and concurrent thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC): Results of the B001-phase III GERCOR-study. Proc Amer Assoc Cancer Res 45, 2004 (abstr 1366)
29. Bradley J, Paulus R, Komaki R: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage IIIA/IIIB nonsmall cell lung cancer: Preliminary findings on radiation dose in RTOG 0617. Presented at the 53rd Annual Meeting of the American Society for Radiation Oncology, Miami, FL, October 2-6, 2011 (abstr LBA 2)
30. Stinchcombe TE, Hodgson L, Herndon JE 2nd, et al: Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:1117-1125, 2009
31. Atagi S, Kawahara M, Tamura T, et al: Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: A phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 35:195-201, 2005 (Pubitemid 40796853)
32. Jeremic B, Shibamoto Y, Milicic B, et al: A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 44:343-348, 1999 (Pubitemid 29205032)
33. Langer CJ, Hsu C, Curran WJ, et al: Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 21:299a, 2002 (abstr 1193)
34. Schild SE, Mandrekar SJ, Jatoi A, et al: The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 110:363-368, 2007 (Pubitemid 47121897)
35. Okamoto H, Kawahara M, Yokoyama A, et al: Updated results of a phase III trial comparing standard thoracic radiotherapy (RT) with or without concurrent daily low-dose carboplatin in elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC): JCOG0301. J Clin Oncol 30:455s, 2012 (suppl 15; abstr 7017)
36. Bradley JD, Scott CB, Paris KJ, et al: A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys 52:1173-1179, 2002 (Pubitemid 34302878)
37. Gore E, Bae K, Langer C, et al: Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: Radiation Therapy Oncology Group 0213. Clin Lung Cancer 12:125-130, 2011
38. Hallqvist A, Wagenius G, Rylander H, et al: Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite-A phase II study from the Swedish Lung Cancer Study Group. Lung Cancer 71:166-172, 2011
39. Hughes S, Liong J, Miah A, et al: A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 3:648-651, 2008 (Pubitemid 351787311)
40. Jatoi A, Schild SE, Foster N, et al: A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol 21:2040-2044, 2010
41. Jensen AD, Munter MW, Bischoff HG, et al: Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: The NEAR trial. Cancer 117:2986-2994, 2011
42. Kotsakis AP, Ramalingam SS, Tarhini AA, et al: Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 29: 457s, 2011 (suppl 15; abstr 7019)
43. Ready N, Janne PA, Bogart J, et al: Chemoradiotherapy and gefitinib in stage III non-small celllung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and leukemia group B (CALGB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 5:1382-1390, 2010
44. Choong NW, Mauer AM, Haraf DJ, et al: Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 3:1003-1011, 2008
45. Rothschild S, Bucher SE, Bernier J, et al: Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: A phase I trial. Int J Radiat Oncol Biol Phys 80:126-132, 2011
46. Komaki R, Blumenschein GR, Wistuba II, et al: Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III nonsmall cell lung cancer. J Clin Oncol 29:458s, 2011 (suppl 15; abstr 7020)
47. Stinchcombe TE, Morris DE, Lee CB, et al: Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose threedimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 3:250-257, 2008 (Pubitemid 351654324)
48. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
49. Rigas J, Carey M, Rubin M: Efficacy of maintenance erlotinib versus placebo in patients with unresectable stage III non-small cell lung cancer (NSLC) following concurrent chemoradiation. J Thorac Oncol 4, 2009 (abstr C6.1)
50. Ball D, Burmeister B, Mitchell P, et al: Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non small cell lung cancer (CRITICAL). J Thorac Oncol 2:S633-S634, 2007
51. Center B, Petty WJ, Ayala D, et al: A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol 5:69-74, 2010
52. Morita S, Okamoto I, Kobayashi K, et al: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15:4493-4498, 2009
53. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
54. Mak RH, Doran E, Muzikansky A, et al: Outcomes after combined modality therapy for EGFRmutant and wild-type locally advanced NSCLC. Oncologist 16:886-895, 2011
55. Blumenschein GR Jr, Paulus R, Curran WJ, et al: Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B nonsmall-cell lung cancer: RTOG 0324. J Clin Oncol 29:2312-2318, 2011
56. van den Heuvel MM, Uyterlinde W, Aerts J, et al: A randomized, multicenter phase II study investigating additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Reporting on the efficacy. J Clin Oncol 30:456s, 2012 (suppl 15; abstr 7019)
57. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
58. Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804-1809, 2010
59. Spigel DR, Hainsworth JD, Yardley DA, et al: Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28:43-48, 2010
60. Stinchcombe T, Socinski M, Moore D, et al: Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). J Clin Oncol 29:457s, 2011 (suppl 15; abstr 7016)
61. Lu C, Lee JJ, Komaki R, et al: Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: A randomized phase III trial. J Natl Cancer Inst 102:859-865, 2010
62. Hoang T, Dahlberg SE, Schiller JH, et al: Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: The ECOG 3598 study. J Clin Oncol 30:616-622, 2012
63. Choy H, Nabid A, Stea B, et al: Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23:5918-5928, 2005
64. Butts C, Maksymiuk A, Goss G, et al: A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): Updated survival analysis. J Thorac Oncol 2:S332-S333, 2007 (suppl 4)
65. Brunsvig PF, Kyte JA, Kersten C, et al: Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 17:6847-6857, 2011
66. Shumway D, Corbin K, Salgia R, et al: Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer 74:446-450, 2011
67. Ung Y, Gu C, Cline K, et al: An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. J Clin Oncol 29:457s, 2011 (suppl 15; abstr 7018)
68. Bradley J, Bae K, Choi N, et al: A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys 82:435-441, 2012
69. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 10:S239-S244, 1994 (suppl 1) (Pubitemid 24140376)
70. Bradley JD, Moughan J, Graham MV, et al: A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: Phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 77:367-372, 2010
71. Schild SE, McGinnis WL, Graham D, et al: Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65:1106-1111, 2006
72. Socinski MA, Blackstock AW, Bogart JA, et al: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and doseescalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457-2463, 2008
73. Machtay M, Paulus R, Moughan J, et al: Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 7:716-722, 2012
74. Schild SE, Stella PJ, Geyer SM, et al: Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:370-378, 2002 (Pubitemid 35286800)
75. Belani CP, Wang W, Johnson DH, et al: Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23:3760-3767, 2005
76. Hatton M, Nankivell M, Lyn E, et al: Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (chart) for patients with locally advanced inoperable non-small-cell lung cancer: The MRC INCH randomized trial. Int J Radiat Oncol Biol Phys 81:712-718, 2011
77. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in nonsmall-cell lung cancer: A randomised multicentre trial-CHART Steering Committee. Lancet 350:161-165, 1997 (Pubitemid 27303621)
78. Yuan S, Sun X, Li M, et al: A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 30:239-244, 2007 (Pubitemid 46884142)
79. Bogart JA, Hodgson L, Seagren SL, et al: Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol 28:202-206, 2010
80. Belderbos J, Uitterhoeve L, van Zandwijk N, et al: Randomised trial of sequential vs. concurrent chemo-radiotherapy in patients with inoperable NSCLC (EORTC 08972-22973). Eur J Cancer 43:114-121, 2007 (Pubitemid 46054477)
81. Cho KH, Ahn SJ, Pyo HR, et al: A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable stage III non-small-cell lung cancer: Results of Korean Radiation Oncology Group 0301 study. Int J Radiat Oncol Biol Phys 74:1397-1404, 2009
82. Maguire J, McMenemin R, O'Rourke N: SOCCAR: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC. J Clin Oncol 29:462s, 2011 (suppl; abstr 7039)
83. Onishi H, Shirato H, Nagata Y, et al: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2:S94-S100, 2007 (Pubitemid 47183602)
84. Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-1076, 2010
85. Bradley JD, Wahab S, Lockett MA, et al: Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys 56:342-347, 2003 (Pubitemid 36542891)
86. Bradley J: Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2:S118-S124, 2007 (Pubitemid 47183606)
87. Timmerman R, McGarry R, Yiannoutsos C, et al: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833-4839, 2006 (Pubitemid 46630909)
88. Nath SK, Sandhu AP, Kim D, et al: Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiother Oncol 99:12-17, 2011
89. Chang JY, Komaki R, Lu C, et al: Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 117:4707-4713, 2011
90. Oshiro Y, Mizumoto M, Okumura T, et al: Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 7:370-375, 2012
91. Sheets NC, Goldin GH, Meyer AM, et al: Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307:1611-1620, 2012
92. Mehta N, Mauer AM, Hellman S, et al: Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment. Int J Oncol 25:1677-1683, 2004
93. Rusthoven KE, Hammerman SF, Kavanagh BD, et al: Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 48:578-583, 2009
94. Cheruvu P, Metcalfe SK, Metcalfe J, et al: Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiat Oncology 6:80, 2011
95. Hasselle MD, Haraf DJ, Rusthoven KE, et al: Hypofractionated image-guided radiation therapy for patients with limited volume metastatic nonsmall cell lung cancer. J Thorac Oncol 7:376-381, 2012
96. Lussier YA, Xing HR, Salama JK, et al: MicroRNA expression characterizes oligometastasis (es). PloS One 6:e28650, 2011